Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Acquires 15,321 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc purchased 15,321 shares of the firm’s stock in a transaction that occurred on Friday, March 27th. The shares were acquired at an average cost of $26.61 per share, with a total value of $407,691.81. Following the completion of the transaction, the insider directly owned 142,360 shares of the company’s stock, valued at $3,788,199.60. The trade was a 12.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc purchased 9,533 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $25.86 per share, with a total value of $246,523.38.
• On Thursday, March 26th, Millennium Management Llc purchased 5,731 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $34.49 per share, with a total value of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $28.16 per share, with a total value of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Trading Up 3.1%

Shares of SNSE traded up $0.61 on Friday, reaching $20.43. 40,084 shares of the company’s stock traded hands, compared to its average volume of 223,112. The stock has a market cap of $27.40 million, a PE ratio of -1.23 and a beta of -0.18. The stock’s 50 day simple moving average is $29.11 and its two-hundred day simple moving average is $17.85. Sensei Biotherapeutics, Inc. has a 52-week low of $5.25 and a 52-week high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Analysts forecast that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,041 shares of the company’s stock after acquiring an additional 20,525 shares during the period. Renaissance Technologies LLC owned approximately 2.39% of Sensei Biotherapeutics worth $1,010,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analysts Set New Price Targets

SNSE has been the subject of several research reports. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners initiated coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $40.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.